COVID-19 Vaccines: Interim Analysis of Phase III trials in UK
COVID-19 Vaccines: Interim Analysis of Phase III trials in UK
COVID-19 Vaccines: Interim Analysis of Phase III trials in UK. The Lancet publishes the interim analysis results of the Phase III clinical trial of COVID-19 vaccine in the UK
This vaccine, led by researchers at the University of Oxford, has “acceptable safety” and can enable vaccinators to produce a strong immune response to the new coronavirus.
The British medical journal “The Lancet” published on the 8th the results of the interim analysis of a phase III clinical trial of a COVID-19 vaccine, showing that the vaccine developed by researchers at Oxford University has “acceptable safety” and can make the vaccinated Produce a strong immune response to the new coronavirus.
The vaccine, called AZD1222, was developed by a team such as the Jenner Institute of Oxford University. The vaccine clinical trial started in late April this year. Subsequently, the developer reached an agreement with AstraZeneca Pharmaceuticals to conduct in-depth cooperation on the global development, production and distribution of the candidate vaccine.
The results of the interim analysis showed that after the subjects received two doses of the standard dose of this vaccine, the effectiveness against the new coronavirus can reach 62%; and if one dose of the low dose vaccine followed by a standard dose of this vaccine, Effective performance reaches 90%.
According to the report, the team’s analysis of the effectiveness of the vaccine is based on data from 11,636 volunteers who participated in clinical trials in the UK and Brazil and received two doses of vaccination. The team’s analysis of vaccine safety is based on data from more than 23,000 volunteers participating in clinical trials in the United Kingdom, Brazil, and South Africa. Three of them had serious side effects that may be related to the vaccine, but they have all recovered or are recovering.
One of the authors of the report, Dr. Merrion Wojci of Oxford University, said that this is the interim result of a phase III clinical trial. The trial is still ongoing and the team will analyze more data.
(source:xinhuawang)
Disclaimer of medicaltrend.org
